Hereditary Angioedema Drug Pipeline Analysis Report 2025

According to the Rare Disease Advisor, the prevalence of hereditary angioedema is estimated to be between 1 in 10,000 and 1 in 50,000. Every year, HAE episodes cause 15,000 to 30,000 visits to emergency rooms in the United States. It makes up around 2% of all cases of clinical angioedema, which afflicts about 20% of the population. Several companies are engaged in research initiatives to address the need for effective treatment for the rare disorder.

Report Coverage

The Hereditary Angioedema Drug Pipeline Report by the publisher gives comprehensive insights into hereditary angioedema drugs currently undergoing hereditary angioedema clinical trials. It covers various aspects related to the details of each of these hereditary angioedema drugs under development. The report includes the analysis of over 20 pipeline drugs and 10+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from hereditary angioedema.

The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration, and ongoing hereditary angioedema pipeline development activities.

Hereditary Angioedema Drug Pipeline Outlook

Hereditary angioedema is a rare genetic disorder that is primarily caused by a mutation in the SERPING1 gene which is responsible for the functioning of the C1 inhibitor protein. Improper functioning of this protein results in inflammation in various body parts, such as the face, gastrointestinal tract, limbs and airway. As a result of this altered mechanism, there is an overabundance of the peptide bradykinin, which increases vascular permeability and leads to swelling and fluid buildup. The disorder can lead to some severe complications including airway obstruction. The symptoms typically begin in childhood with episodes lasting for a few days to a few weeks.

Hereditary angioedema treatment includes the management of acute crises and the provision of long-term prophylaxis. Acute attacks are typically managed using C1-inhibitors such as Berinert and Ruconest. Earlier, danazol was used for the management of prophylaxis. However, more effective and safer options such as lanadelumab and berotralstat are preferred. There is a need for drugs that can be used in airway management, particularly in emergency situations. Moreover, several companies and institutes are developing novel therapies to manage the disease. For instance, a trial is investigating the efficacy and safety of a subcutaneous drug that could be useful in emergency situations. The presence of various clinical trials for hereditary angioedema ha s influenced the pipeline landscape positively.

Hereditary Angioedema - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of hereditary angioedema drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 20+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The hereditary angioedema therapeutic assessment report covers 20+ drug analyses based on molecule type:

• Gene Therapy
• Small Molecule
• Polymers
• Vaccine
• Peptides
• Monoclonal Antibody

By Route of Administration

The pipeline assessment report covers 20+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Hereditary Angioedema - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for hereditary angioedema with 5 drugs in phase II.

Hereditary Angioedema Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under hereditary angioedema pipeline analysis include gene therapies, small molecules, vaccines, polymers, peptides and monoclonal antibodies. Several trials are ongoing to assess the efficacy of gene therapies. Studies show that gene therapies have been highly effective in the management of the disease. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for hereditary angioedema.

Hereditary Angioedema Clinical Trials Assessment - Competitive Dynamics

The hereditary angioedema report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in hereditary angioedema clinical trials:

• Astria Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Intellia Therapeutics
• KalVista Pharmaceuticals, Ltd.
• CSL Behring
• BioCryst Pharmaceuticals
• BioMarin Pharmaceutical
• Takeda Pharmaceutical Industries, Ltd.
• Pharvaris Netherlands B.V.

Hereditary angioedema - Pipeline Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for hereditary angioedema. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hereditary angioedema drug candidates.

Drug: KVD900

The trial is designed to investigate the clinical efficacy of KVD900 and to evaluate the long-term safety of the drug The trial is sponsored by KalVista Pharmaceuticals, Ltd. and is currently under phase III.

Drug: CSL312

The objective of the study is to assess the efficacy and long-term safety of hereditary angioedema drug candidate CSL312 when administered subcutaneously. The trial is sponsored by CSL Behring and is currently under phase III.

Drug: Berotralstat

BioCryst Pharmaceuticals is developing the drug and is currently under phase III. The study is being designed to evaluate the pharmacokinetics and safety of the drug.

Reasons To Buy This Report

The Hereditary angioedema Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hereditary angioedema. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hereditary angioedema collaborations, regulatory environments, and potential growth opportunities within hereditary angioedema pipeline insights.

Key Questions Answered in the Hereditary Angioedema - Pipeline Assessment Report

• Which companies/institutions are leading the hereditary angioedema drug development?
• What is the efficacy and safety profile of hereditary angioedema pipeline drugs?
• Which company is leading the hereditary angioedema pipeline development activities?
• What is the current hereditary angioedema commercial assessment?
• What are the opportunities and challenges present in the hereditary angioedema drug pipeline landscape?
• What is the efficacy and safety profile of hereditary angioedema pipeline drugs?
• Which company is conducting major trials for hereditary angioedema drugs?
• Which companies/institutions are involved in hereditary angioedema collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hereditary angioedema?

This product will be delivered within 3-5 business days.